How unmeasured confounding in a competing risks setting can affect treatment effect estimates in observational studies.


Journal

BMC medical research methodology
ISSN: 1471-2288
Titre abrégé: BMC Med Res Methodol
Pays: England
ID NLM: 100968545

Informations de publication

Date de publication:
31 07 2019
Historique:
received: 02 11 2018
accepted: 17 07 2019
entrez: 2 8 2019
pubmed: 2 8 2019
medline: 11 6 2020
Statut: epublish

Résumé

Analysis of competing risks is commonly achieved through a cause specific or a subdistribution framework using Cox or Fine & Gray models, respectively. The estimation of treatment effects in observational data is prone to unmeasured confounding which causes bias. There has been limited research into such biases in a competing risks framework. We designed simulations to examine bias in the estimated treatment effect under Cox and Fine & Gray models with unmeasured confounding present. We varied the strength of the unmeasured confounding (i.e. the unmeasured variable's effect on the probability of treatment and both outcome events) in different scenarios. In both the Cox and Fine & Gray models, correlation between the unmeasured confounder and the probability of treatment created biases in the same direction (upward/downward) as the effect of the unmeasured confounder on the event-of-interest. The association between correlation and bias is reversed if the unmeasured confounder affects the competing event. These effects are reversed for the bias on the treatment effect of the competing event and are amplified when there are uneven treatment arms. The effect of unmeasured confounding on an event-of-interest or a competing event should not be overlooked in observational studies as strong correlations can lead to bias in treatment effect estimates and therefore cause inaccurate results to lead to false conclusions. This is true for cause specific perspective, but moreso for a subdistribution perspective. This can have ramifications if real-world treatment decisions rely on conclusions from these biased results. Graphical visualisation to aid in understanding the systems involved and potential confounders/events leading to sensitivity analyses that assumes unmeasured confounders exists should be performed to assess the robustness of results.

Sections du résumé

BACKGROUND
Analysis of competing risks is commonly achieved through a cause specific or a subdistribution framework using Cox or Fine & Gray models, respectively. The estimation of treatment effects in observational data is prone to unmeasured confounding which causes bias. There has been limited research into such biases in a competing risks framework.
METHODS
We designed simulations to examine bias in the estimated treatment effect under Cox and Fine & Gray models with unmeasured confounding present. We varied the strength of the unmeasured confounding (i.e. the unmeasured variable's effect on the probability of treatment and both outcome events) in different scenarios.
RESULTS
In both the Cox and Fine & Gray models, correlation between the unmeasured confounder and the probability of treatment created biases in the same direction (upward/downward) as the effect of the unmeasured confounder on the event-of-interest. The association between correlation and bias is reversed if the unmeasured confounder affects the competing event. These effects are reversed for the bias on the treatment effect of the competing event and are amplified when there are uneven treatment arms.
CONCLUSION
The effect of unmeasured confounding on an event-of-interest or a competing event should not be overlooked in observational studies as strong correlations can lead to bias in treatment effect estimates and therefore cause inaccurate results to lead to false conclusions. This is true for cause specific perspective, but moreso for a subdistribution perspective. This can have ramifications if real-world treatment decisions rely on conclusions from these biased results. Graphical visualisation to aid in understanding the systems involved and potential confounders/events leading to sensitivity analyses that assumes unmeasured confounders exists should be performed to assess the robustness of results.

Identifiants

pubmed: 31366331
doi: 10.1186/s12874-019-0808-7
pii: 10.1186/s12874-019-0808-7
pmc: PMC6668192
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

166

Références

Nephrol Dial Transplant. 2015 Sep;30(9):1418-23
pubmed: 25324358
Lancet. 2005 Jan 1-7;365(9453):82-93
pubmed: 15639683
Lifetime Data Anal. 2009 Jun;15(2):278-94
pubmed: 19109770
Epidemiology. 2017 Jan;28(1):20-27
pubmed: 27748680
Biometrics. 2013 Dec;69(4):850-60
pubmed: 24224574
Stat Methods Med Res. 2019 Feb;28(2):357-371
pubmed: 28835193
Stat Med. 2006 Dec 30;25(24):4279-92
pubmed: 16947139
Kidney Int. 2007 Sep;72(6):671-5
pubmed: 17597701
Stat Med. 2007 May 20;26(11):2389-430
pubmed: 17031868
BMJ. 2007 Dec 1;335(7630):1134
pubmed: 17986716
Int J Epidemiol. 2012 Dec;41(6):1694-705
pubmed: 23064412
Am J Epidemiol. 2007 Sep 15;166(6):646-55
pubmed: 17615092
BMJ. 2017 May 23;357:j2099
pubmed: 28536104
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
Stat Med. 2010 Mar 30;29(7-8):875-84
pubmed: 20213713
Eur J Epidemiol. 2013 Jul;28(7):557-67
pubmed: 23700026
Stat Med. 2013 Oct 15;32(23):4118-34
pubmed: 23613458
Int J Epidemiol. 2010 Feb;39(1):107-17
pubmed: 19948779
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
J Clin Epidemiol. 2016 Jan;69:217-24
pubmed: 26327488
Stat Med. 2007 Feb 28;26(5):965-74
pubmed: 16755533
Stat Med. 2012 May 20;31(11-12):1089-97
pubmed: 21953401

Auteurs

Michael Andrew Barrowman (MA)

University of Manchester, Vaughan House, Portsmouth Street, Manchester, M13 9GB, UK. michael.barrowman@manchester.ac.uk.

Niels Peek (N)

University of Manchester, Vaughan House, Portsmouth Street, Manchester, M13 9GB, UK.

Mark Lambie (M)

Institute for Science and Technology in Medicine, Keele University, Stoke-on-Trent, ST4 7QB, UK.

Glen Philip Martin (GP)

University of Manchester, Vaughan House, Portsmouth Street, Manchester, M13 9GB, UK.

Matthew Sperrin (M)

University of Manchester, Vaughan House, Portsmouth Street, Manchester, M13 9GB, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH